|
OncoMed Pharmaceuticals, Inc. is a public American pharmaceutical company headquartered in Redwood City, California.〔 The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha.〔〔 , the company had 83 employees.〔 OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells".〔 The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company.〔 OncoMed went public in 2013 and is listed on NASDAQ under the stock symbol OMED.〔〔 ==History== In 2007, Oncomed consolidated its operations located in Mountain View and Palo Alto, California onto the single headquarters campus in Redwood City.〔 One of the buildings on the new campus was the former home of NeXT.〔 In 2012, OncoMed sponsored the USAN nonproprietary name vantictumab for a human IgG2 anti-Frizzled antibody, an anti-cancer therapeutic.〔 In the same year, the company sponsored the USAN name demcizumab for a human IgG2 anti-DLL4 antibody, also an anti-cancer therapeutic.〔 In 2014, OncoMed entered into an anti-cancer stem cell therapeutic development agreement with Celgene encompassing demcizumab and five other biologics from OncoMed's pipeline.〔〔 , co-founder Max Wicha was the director of the University of Michigan Comprehensive Cancer Center and remained a consultant to OncoMed, while co-founder Michael Clarke had taken up a position at Stanford University.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「OncoMed」の詳細全文を読む スポンサード リンク
|